



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/469,606 12/22/99 VOLLMERS

H PATWA-2

EXAMINER

HOLLERAN, A

ART UNIT

PAPER NUMBER

1642

DATE MAILED:

11/21/00

HM12/1121  
MILLEN WHITE ZELANO & BRANIGAN PC  
ARLINGTON COURTHOUSE PLAZA I  
SUITE 1400  
2200 CLARENDON BOULEVARD  
ARLINGTON VA 22201

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trad marks**

# Office Action Summary

Application No.

09/469,606

Applicant(s)

Vollmers et al

Examiner

Anne Holleran

Group Art Unit

1642



☐ Responsive to communication(s) filed on \_\_\_\_\_

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1035 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 1 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claim

☒ Claim(s) 1-29 is/are pending in the application

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration

☐ Claim(s) \_\_\_\_\_ is/are allowed.

☐ Claim(s) \_\_\_\_\_ is/are rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☒ Claims 1-29 are subject to restriction or election requirement.

## Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some\* ☒ None of the CERTIFIED copies of the priority documents have been

☐ received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_.

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

☐ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

— SEE OFFICE ACTION ON THE FOLLOWING PAGES —

---

**DETAILED ACTION**

***Election/Restriction***

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1- 4, drawn to a glycoprotein comprising at least one section of CD55 and a tumor specific glycostructure; and to a process for obtaining, classified in class 530, subclass 395.
  - II. Claims 5, 6, 10-13, 17, 18 and 9(to the extent that claim 9 reads on a method of claim 5 or 6), drawn to uses that test the ability of a substance to bind to a glycoprotein, classified in class 435, subclass 7.1.
  - III. Claims 7, 23, 25 and 9(to the extent that claim 9 reads on a method of claim 7), drawn to uses that test the ability of a substance to induce apoptosis, classified in class 435, subclass 4.
  - IV. Claims 8, 21, 22 and 26-29, and 9(to the extent that claim 9 reads on a method of claim 8) drawn to uses that test the ability of a substance to induce a phosphorylation cascade mediated by CD55, classified in class 435, subclass 4.
  - V. Claims 14-16, drawn to uses of substances which bind specifically to a glycoprotein for the production of agents, classified in class 530, subclass 387.1.
  - VI. Claims 19 and 24, drawn to processes for combating tumors, classified in class 514, subclass 2.

---

VII. Claim 20, drawn to a process for diagnosis of tumors, classified in class 436, subclass 64.

2. The inventions are distinct, each from the other, for the following reasons:

Each of inventions II-VII is directed to a separate and distinct process. Each of the processes are distinct both physically and functionally, require different steps and make or use different products. Each of inventions II-VII are drawn to processes (use is interpreted to be methods or processes) which require different method steps and make and use different products and have different end-points. For example, testing for the ability to induce apoptosis is materially different method from a method for testing for binding, testing for the induction of phosphorylation, a process for combating tumors, a process for diagnosis of a tumor and to uses of substances which bind to a protein because each of these methods requires different method steps.

The product of invention I appears to be related to the uses, processes and method of inventions of groups II-VII. Thus, Invention I and inventions II-VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the many separate and distinct methods of use show that the claimed products can be used in materially different process of using.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and recognized divergent subject matter and because searches required for the groups are not co-extensive, restriction for examination purposes as indicated is proper.

4. Applicant is advised that the reply to this requirement, to be complete, must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Anne Holleran, Ph.D. whose telephone number is (703) 308-8892.

Examiner Holleran can normally be reached Monday through Friday, 9:00 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, Ph.D. can be reached at (703) 308-3995.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist at telephone number (703) 308-0196.

*ALH*  
Anne L. Holleran  
Patent Examiner  
November 20, 2000

*Brenda Brumback*  
BRENDA BRUMBACK  
PATENT EXAMINER